SANTHERA PHARMACEUTICALS HOLDING AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.17 CHF | -1.29% |
|
-1.50% | -6.52% |
| Apr. 25 | Transcript : Santhera Pharmaceuticals Holding AG, 2023 Earnings Call, Apr 25, 2024 | |
| Apr. 25 | Santhera Pharmaceuticals Swings to Profit in FY23; Revenue Grows | MT |
Presenter SpeechDario Eklund (Executives)Good afternoon and good morning, everyone. Thank you ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Santhera Pharmaceuticals Holding AG (Santhera) is a Switzerland-based company engaged in the pharmaceutical sector. The Company operates through one business segment, which is the research, development and commercialization of pharmaceutical products for the treatment of neuromuscular and mitochondrial diseases, such as Duchenne muscular dystrophy (DMD) and cystic fibrosis (CF). The Company focuses also on development of gene therapy for the treatment of LAMA2 (Laminin Subunit Alpha 2) deficient congenital muscular dystrophy (CMD). Santhera operates through its wholly owned subsidiaries: Santhera Pharmaceuticals (Schweiz) AG, Liestal, Santhera Pharmaceuticals (USA) Inc, Santhera Pharmaceuticals (Canada) Inc, Santhera Pharmaceutical (Deutschland) GmbH and Oy Santhera Pharmaceuticals (Finland) Ltd.
Sector
Pharmaceuticals
Calendar
2024-05-28
- Annual General Meeting
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
9.17
CHF
Average target price
30
CHF
Spread / Average Target
+227.15%
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -6.52% | 114M | |
| +7.91% | 72.81B | |
| -10.56% | 5.13B | |
| +58.79% | 4.99B | |
| +4.07% | 3.9B | |
| -16.90% | 2.48B | |
| +20.84% | 2.42B | |
| -26.13% | 2.32B | |
| +19.31% | 2.17B | |
| -0.50% | 1.64B |
- Stock Market
- Equities
- SANN Stock
- News Santhera Pharmaceuticals Holding AG
- Transcript : Santhera Pharmaceuticals Holding AG - Special Call